Literature DB >> 9880087

Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect?

T M Karplus1, K G Saag.   

Abstract

Studies suggest that high dose NSAID use may be associated with a reversible impairment of cognition in the elderly. Prolonged NSAID use, on the other hand, may prevent the decline in cognition associated with aging. However, it has yet to be to be definitively determined whether this protection arises from an anti-inflammatory effect that modifies pathways involved in Alzheimer's dementia, or is mediated by a platelet effect that decreases the risk of cerebrovascular disease. Further large-scale, randomised, controlled trials using NSAIDs are needed before patients can be advised that the known risks of NSAIDs are outweighed by their potential long term benefits on cognition. While clinicians await the results of such studies, they should continue to be alert to the possibility of acute CNS adverse effects in their elderly patients who are receiving NSAIDs and to prescribe the minimum dose that is necessary to control pain and inflammation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9880087     DOI: 10.2165/00002018-199819060-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  31 in total

1.  Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group.

Authors:  M M Breteler; C M van Duijn; V Chandra; L Fratiglioni; A B Graves; A Heyman; A F Jorm; E Kokmen; K Kondo; J A Mortimer
Journal:  Int J Epidemiol       Date:  1991       Impact factor: 7.196

2.  Age differences in adults' free recall, cued recall, and recognition.

Authors:  M Perlmutter
Journal:  J Gerontol       Date:  1979-07

3.  A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients.

Authors:  E Pfeiffer
Journal:  J Am Geriatr Soc       Date:  1975-10       Impact factor: 5.562

4.  A case-control study of Alzheimer's disease in Australia.

Authors:  G A Broe; A S Henderson; H Creasey; E McCusker; A E Korten; A F Jorm; W Longley; J C Anthony
Journal:  Neurology       Date:  1990-11       Impact factor: 9.910

5.  The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada.

Authors: 
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

6.  Serological alpha 1-antichymotrypsin in Down's syndrome and Alzheimer's disease.

Authors:  K Brugge; R Katzman; L R Hill; L A Hansen; T Saitoh
Journal:  Ann Neurol       Date:  1992-08       Impact factor: 10.422

7.  Validation of a short Orientation-Memory-Concentration Test of cognitive impairment.

Authors:  R Katzman; T Brown; P Fuld; A Peck; R Schechter; H Schimmel
Journal:  Am J Psychiatry       Date:  1983-06       Impact factor: 18.112

8.  Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly.

Authors:  K G Saag; L M Rubenstein; E A Chrischilles; R B Wallace
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

9.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

10.  Elevated circulating tumor necrosis factor levels in Alzheimer's disease.

Authors:  H Fillit; W H Ding; L Buee; J Kalman; L Altstiel; B Lawlor; G Wolf-Klein
Journal:  Neurosci Lett       Date:  1991-08-19       Impact factor: 3.046

View more
  6 in total

1.  Neuroprotection in Alzheimer's disease - new strategies for treatment.

Authors:  A Nordberg
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV.

Authors:  Norman J Haughey; Xiaomao Zhu; Veera Venkata Ratnam Bandaru
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-08       Impact factor: 4.147

3.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.

Authors:  Barbara K Martin; Christine Szekely; Jason Brandt; Steven Piantadosi; John C S Breitner; Suzanne Craft; Denis Evans; Robert Green; Michael Mullan
Journal:  Arch Neurol       Date:  2008-05-12

4.  Therapeutic approaches to age-associated neurocognitive disorders.

Authors:  R O'Hara; C Derouesné; K N Fountoulakis; J A Yesavage
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

5.  Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer's Dementia in Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study in Taiwan.

Authors:  Cheng-Wei Chang; Jorng-Tzong Horng; Chi-Chang Hsu; Jui-Ming Chen
Journal:  J Diabetes Res       Date:  2016-10-27       Impact factor: 4.011

6.  Anxiety- and activity-related effects of paracetamol on healthy and neuropathic rats.

Authors:  Zuyue Chen; Hong Wei; Antti Pertovaara; Jianhong Wang; Synnöve Carlson
Journal:  Pharmacol Res Perspect       Date:  2018-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.